Navigation Links
Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
Date:1/24/2008

PALATINE, Ill., Jan. 24 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. (OTC Bulletin Board: ACPH.OB) is pleased to announce the appointment of George K. Ross to its Board of Directors and Chairman of its Audit Committee. The appointment of Mr. Ross increases the size of the Company's Board to seven.

Since April 2002, Mr. Ross has been a consultant to early stage businesses and a financial investor. Since July 2005 he has also served as Executive Director, Greater New York for World Vision. His business career has included senior financial officer and board member positions with both public and private companies in diverse industries. Mr. Ross was Executive Vice President and Chief Financial Officer and a board member of Tier Technologies Inc. from February 1997 to January 2000, which became a public company during this period. Mr. Ross was a partner and investor with Capital Partners from 1992 to 1997, serving on multiple boards of directors. He was a senior financial officer and director of various Axel Johnson Inc. businesses from 1979 to 1992. He also served as Executive Vice President and Chief Financial Officer and director of Aminoil USA, an R.J. Reynolds ("RJR") subsidiary, from 1976 to 1979; and in various financial positions with RJR from 1969 to 1976. He also has worked in public accounting with Ernst & Ernst. Mr. Ross is a Certified Public Accountant and earned a Bachelor of Arts degree from Ohio Wesleyan University and a Masters of Business Administration from Ohio State University.

About Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion(R) (abuse deterrent) Technology and related product candidates.

Forward Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. The most significant of such risks and uncertainties include, but are not limited to, the ability of the Company, King Pharmaceuticals Research and Development, Inc. and other pharmaceutical companies, if any, with whom the Company may license its Aversion(R) Technology, to obtain necessary regulatory approvals and commercialize products utilizing the Aversion(R) Technology, the ability to avoid infringement of patents, trademarks and other proprietary rights or trade secrets of third parties, the ability to manufacture products utilizing the Aversion(R) Technology, and the ability to fulfill the FDA's requirements for approving the Company's product candidates for commercial distribution in the United States, including, without limitation, the adequacy of the results of the clinical studies completed to date and the results of other clinical studies, to support FDA approval of the Company's product candidates, the adequacy of the development program for the Company's product candidates, changes in regulatory requirements, adverse safety findings relating to the Company's product candidates, the risk that the FDA may not agree with the Company's analysis of its clinical studies and may evaluate the results of these studies by different methods or conclude that the results of the studies are not statistically significant, clinically meaningful or that there were human errors in the conduct of the studies or otherwise, the risk that further studies of the Company's product candidates are not positive, and the uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process. You are encouraged to review other important risk factors relating to the Company on our web site at http://www.acurapharm.com under the link, "Company Risk Factors" and detailed in Company filings with the Securities and Exchange Commission. Acura Pharmaceuticals, Inc. assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Acura Pharmaceuticals, Inc. press releases may be reviewed at http://www.acurapharm.com.


'/>"/>
SOURCE Acura Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
2. King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion(R) (Abuse-Deterrent) Technology
3. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
4. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
5. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
6. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
8. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
9. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
10. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
11. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 05, 2016 , ... Derrin Doty Group has unveiled the latest charity campaign ... communities west of Seattle. The insurance provider’s caring team has been so moved by ... due to complications from the flu, that they have decided to extend their original ...
(Date:5/5/2016)... ... May 05, 2016 , ... The University of ... to host the 2016 National SACA Leadership Conference on the Portland campus September ... chapter officers to come together and develop skills to be future leaders in ...
(Date:5/5/2016)... ... , ... Vitenas Cosmetic Surgery has been named as one of the eight ... Architects and the Academy of Architecture for Health. The building, brainchild of founder Paul ... patients in October of 2014. , The prestigious Healthcare Design Awards ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dr. Benjamin Stong of Kalos Facial Plastic Surgery, ... Dr. Stong is double board certified and the only facial plastic surgeon in Atlanta ... loss. Non-surgical therapies such as stem cells can be used to provide stabilization to ...
(Date:5/5/2016)... ... 05, 2016 , ... In honor of National Nurses Week 2016, Aya ... United States to thank a nurse who's made a difference in their life. From ... American Red Cross of San Diego/Imperial Counties (up to $10,000) every time someone tells ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... Research and Markets has announced the ... the USA"  report to their offering.  ,     (Logo: ... current Positron Emission Tomography (PET) scanner and cyclotron install ... Along with the current known number of PET scanners ... the report also contains a detailed breakdown of this ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocythemia Market and ... to their offering.       ... ,The latest research Europe Thrombocythemia Market ... provides comprehensive insights into Thrombocythemia pipeline ...
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Thalassaemia Market and ... their offering.       (Logo: ... Europe Thalassaemia Market and Competitive Landscape Highlights ... pipeline products, Thalassaemia epidemiology, Thalassaemia market valuations ...
Breaking Medicine Technology: